Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2010 Jan;21(1):145-55.
doi: 10.1007/s00198-009-0930-1. Epub 2009 May 21.

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

F-E Cotté  1 , P Fardellone, F Mercier, A-F Gaudin, C Roux
Affiliations
Multicenter Study

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

F-E Cotté et al. Osteoporos Int. 2010 Jan.

Abstract

This primary care database survey evaluated whether osteoporotic women treated with bisphosphonates were more adherent to monthly than to weekly treatment. Both compliance (medication possession ratio [MPR]) and persistence (time to discontinuation) were superior in the monthly ibandronate treatment group. Better control of fracture risk may thus be achieved using monthly treatment regimens.

Introduction: Treatment adherence in osteoporosis is poor. The objective of this study was to evaluate whether monthly bisphosphonate treatment provided superior adherence than weekly treatment.

Methods: We analysed medical claims from a national prescription database (Thales). All women aged >45 years receiving a first prescription of monthly ibandronate or weekly bisphosphonates in 2007 were included. Treatment adherence was monitored from initial prescription until January 2008. Compliance was measured by the MPR and persistence by the time from treatment initiation to discontinuation. Multivariate analysis was used to identify variables independently associated with adherence.

Results: Twelve-month persistence rates were 47.5% for monthly ibandronate and 30.4% for weekly bisphosphonates. Compliance was significantly higher in the monthly cohort (MPR = 84.5%) than in the weekly cohort (MPR = 79.4%). After adjustment for potential confounding variables, women with monthly regimens were 37% less likely to be non-persistent (HR = 0.63 [0.56-0.72]) and presented a 5% higher mean MPR (84.5% versus 79.3%, p < 0.001) than women with weekly regimens. Other major factors associated with improved adherence were previous densitometry and calcium or vitamin D supplementation (p < 0.01).

Conclusions: Adherence to bisphosphonates may be superior for monthly treatment than for weekly treatment and may thus provide improved fracture protection.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart illustrating selection of patients evaluated in the database. RIS risedronate, ALEN alendronate
Fig. 2
Fig. 2
Kaplan–Meier analysis of treatment discontinuation with bisphosphonate. Thick line monthly ibandronate cohort, thin line weekly bisphosphonates. A permissible gap of 45 days for monthly ibandronate and 30 days for weekly bisphosphonates was allowed in this analysis
See this image and copyright information in PMC

References

    1. World Health Organization . Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003.
    1. Vik SA, Hogan DB, Patten SB, Johnson JA, Romonko-Slack L, Maxwell CJ. Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs Aging. 2006;23:345–356. doi: 10.2165/00002512-200623040-00007. - DOI - PubMed
    1. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023–1031. doi: 10.1007/s00198-006-0322-8. - DOI - PubMed
    1. Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D, Hughes N, Kaufman JM, Korte S, Kreutz G, Laslop A, Mitlak B, Rabenda V, Rizzoli R, Santora A, Schimmer R, Tsouderos Y, Viethel P, Reginster JY. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007;18:1311–1317. doi: 10.1007/s00198-007-0410-4. - DOI - PubMed
    1. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–47. - PubMed

Publication types

MeSH terms